title: [Phase II study of Vindesine in patients with hematological malignancy].
abstract: At Saitama Cancer Center a Phase II study of Vindesine was carried out in 18 patients with hematological malignancy being refractory to standard chemotherapies. Vindesine (VDS) was given weekly at a dose of 3 mg/m2 as single-agent chemotherapy. One cytoreduction effect (CE) in 5 patients with acute lympho blastic leukemia, two CEs in 2 patients with acute non-lymphocytic leukemia, one PR and one CE in 4 patients with CML/BC, three PRs in 3 patients with diffuse non-Hodgkin's lymphoma (NHL) of large cell type, one CR in 2 patients with lymphoblastic lymphoma and one PR in 2 patients with Burkitt's lymphoma were obtained. VDS was discontinued in two patients because of neurologic toxicities such as incontinence of urine, abdominal distension, and severe constipation.
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014751:Vindesine
chemical_list: D000970:Antineoplastic Agents; D014747:Vinblastine; D014751:Vindesine